• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实体瘤合并静脉血栓栓塞症患者特征:基于 1482 例的 10 年回顾性横断面研究。

Profile of Solid Tumor Patients Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study Based on 1482 Cases.

机构信息

Department of Respiratory and Neurology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.

出版信息

Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231169514. doi: 10.1177/10760296231169514.

DOI:10.1177/10760296231169514
PMID:37062945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10116012/
Abstract

The aim of this single-centre 10-year retrospective observational study was to evaluate the profile of Chinese cancerous patients complicated with venous thromboembolism (VTE) based on demographic features, clinical characteristics, and medication exposure. Consecutive 1482 patients with solid tumor complicated with VTE at a tertiary center between 2012 and 2021 were retrospectively enrolled. Data were collected on demographics, comorbidities, discharge diagnoses, laboratory examination data, treatment details, and imaging description of the lesion. The overall incidence of clinical VTE was 1.35% in hospitalized patients with cancer in our center. Lung cancer was the most frequent tumor subtype for developing VTE events, accounting for 24.83% of all cases. Over half of the patients (66.60%) were observed to have an increased risk of VTE within the first 6 months of cancer diagnosis. Close to half of the patients (46.49%) had received chemotherapy within 6 months prior to the diagnosis of VTE. The frequency of massive ascites group (>2000 mL) in gynecological patients with VTE was significantly larger than that of nonmassive ascites group (≤2000 mL) ( < .001). Patients with ovarian, vulvar, lung cancers were considered at high risk for VTE. The assessment and monitoring of VTE in patients with cancer within the first 6 months of cancer diagnosis should be strengthened. VTE occurrence was closely related to advanced age and stage, adenocarcinoma, obesity and noval anticancer therapies in patients with cancer. Early detection of VTE-related examination may lead to earlier intervention for patients with gynecological tumors with preoperative massive ascites.

摘要

本单中心 10 年回顾性观察研究旨在评估中国癌症合并静脉血栓栓塞症(VTE)患者的特征,包括人口统计学特征、临床特征和药物暴露情况。回顾性纳入 2012 年至 2021 年在一家三级中心因实体瘤合并 VTE 住院的 1482 例患者。收集人口统计学、合并症、出院诊断、实验室检查数据、治疗细节和病变的影像学描述等数据。在本中心住院的癌症患者中,临床 VTE 的总体发生率为 1.35%。肺癌是发生 VTE 事件最常见的肿瘤亚型,占所有病例的 24.83%。超过一半的患者(66.60%)在癌症诊断后的前 6 个月内被观察到存在 VTE 风险增加。近一半的患者(46.49%)在 VTE 诊断前 6 个月内接受过化疗。妇科 VTE 患者中大量腹水组(>2000 mL)的频率明显大于非大量腹水组(≤2000 mL)( < .001)。卵巢癌、外阴癌、肺癌患者被认为存在 VTE 高风险。应加强对癌症患者在癌症诊断后 6 个月内的 VTE 评估和监测。VTE 的发生与年龄较大、晚期、腺癌、肥胖和新型抗癌治疗密切相关。对术前大量腹水的妇科肿瘤患者进行 VTE 相关检查的早期发现可能会更早地对其进行干预。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/7cd0fce1f5c4/10.1177_10760296231169514-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/464d6b648adc/10.1177_10760296231169514-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/1c80fc675e10/10.1177_10760296231169514-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/d7f2a4deade9/10.1177_10760296231169514-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/114a4a74dd39/10.1177_10760296231169514-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/7cd0fce1f5c4/10.1177_10760296231169514-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/464d6b648adc/10.1177_10760296231169514-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/1c80fc675e10/10.1177_10760296231169514-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/d7f2a4deade9/10.1177_10760296231169514-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/114a4a74dd39/10.1177_10760296231169514-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddad/10116012/7cd0fce1f5c4/10.1177_10760296231169514-fig5.jpg

相似文献

1
Profile of Solid Tumor Patients Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study Based on 1482 Cases.实体瘤合并静脉血栓栓塞症患者特征:基于 1482 例的 10 年回顾性横断面研究。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231169514. doi: 10.1177/10760296231169514.
2
Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study.实体瘤合并静脉血栓栓塞症:一项 10 年回顾性横断面研究。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620975484. doi: 10.1177/1076029620975484.
3
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer.卵巢癌新辅助化疗期间静脉血栓栓塞的发生率及患者特征
J Thromb Thrombolysis. 2022 Jan;53(1):202-207. doi: 10.1007/s11239-021-02511-6. Epub 2021 Jun 29.
4
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).肺癌静脉血栓栓塞症和早期死亡率的预测因素:一项全球前瞻性研究(CANTARISK)的结果。
Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.
5
Incidence and Clinical Characteristic of Venous Thromboembolism in Gynecologic Oncology Patients attending King Chulalongkorn Memorial Hospital over a 10 Year Period.朱拉隆功国王纪念医院10年间妇科肿瘤患者静脉血栓栓塞的发病率及临床特征
Asian Pac J Cancer Prev. 2015;16(15):6705-9. doi: 10.7314/apjcp.2015.16.15.6705.
6
[Risk factors of lung cancer complicated with symptomatic venous thromboembolism].[肺癌合并有症状静脉血栓栓塞症的危险因素]
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Jun;39(6):454-8. doi: 10.3760/cma.j.issn.1001-0939.2016.06.010.
7
Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer.卵巢癌患者术前静脉血栓栓塞症和肺栓塞的发生率及危险因素。
Thromb Res. 2020 Jun;190:129-134. doi: 10.1016/j.thromres.2020.02.019. Epub 2020 Mar 4.
8
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗肺癌患者的静脉血栓栓塞发生率和 Khorana 评分的鉴别能力。
J Thromb Thrombolysis. 2022 Aug;54(2):287-294. doi: 10.1007/s11239-022-02649-x. Epub 2022 Apr 8.
9
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy.门诊癌症患者化疗时伴发的静脉血栓栓塞症。
Thromb Haemost. 2010 Nov;104(5):1049-54. doi: 10.1160/TH10-05-0277. Epub 2010 Aug 30.
10
Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.亚洲非小细胞肺癌患者静脉血栓栓塞的危险因素及预后影响
Thromb Haemost. 2014 Jun;111(6):1112-20. doi: 10.1160/TH13-11-0956. Epub 2014 Jan 30.

引用本文的文献

1
Postoperative venous thromboembolism risk in patients with vulvar carcinoma: An analysis of the National surgical Quality Improvement Program (NSQIP) database.外阴癌患者术后静脉血栓栓塞风险:一项基于国家外科质量改进计划(NSQIP)数据库的分析
Gynecol Oncol Rep. 2024 May 12;54:101411. doi: 10.1016/j.gore.2024.101411. eCollection 2024 Aug.

本文引用的文献

1
Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.基于列线图的肺癌住院患者静脉血栓栓塞症新型风险评估模型的推导、验证与评估:一项回顾性病例对照研究
Front Oncol. 2022 Oct 10;12:988287. doi: 10.3389/fonc.2022.988287. eCollection 2022.
2
ABO blood group type and risk of venous thromboembolism in patients with cancer.ABO 血型与癌症患者静脉血栓栓塞风险的关系。
Blood Adv. 2022 Dec 27;6(24):6274-6281. doi: 10.1182/bloodadvances.2021006283.
3
The Interplay of Race/Ethnicity and Obesity on the Incidence of Venous Thromboembolism.
种族/民族和肥胖对静脉血栓栓塞发生率的相互影响。
Am J Prev Med. 2022 Jul;63(1):e11-e20. doi: 10.1016/j.amepre.2021.12.023. Epub 2022 Mar 5.
4
Immune checkpoint inhibitors for cancer and venous thromboembolic events.用于癌症治疗的免疫检查点抑制剂与静脉血栓栓塞事件
Eur J Cancer. 2021 Oct 15;158:99-110. doi: 10.1016/j.ejca.2021.09.010.
5
Thrombotic Complications Associated with Immune Checkpoint Inhibitors.与免疫检查点抑制剂相关的血栓性并发症
Cancers (Basel). 2021 Sep 14;13(18):4606. doi: 10.3390/cancers13184606.
6
Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.癌症免疫疗法导致静脉血栓栓塞发生率增加。
Med. 2021 Apr 9;2(4):423-434. doi: 10.1016/j.medj.2021.02.002. Epub 2021 Mar 12.
7
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis.癌症患者与非癌症患者的动脉和静脉血栓栓塞风险比较——一项全国性分析。
Eur Heart J. 2021 Jun 14;42(23):2299-2307. doi: 10.1093/eurheartj/ehab171.
8
Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study.实体瘤合并静脉血栓栓塞症:一项 10 年回顾性横断面研究。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620975484. doi: 10.1177/1076029620975484.
9
Overall and abdominal obesity in relation to venous thromboembolism.总体肥胖和腹部肥胖与静脉血栓栓塞的关系。
J Thromb Haemost. 2021 Feb;19(2):460-469. doi: 10.1111/jth.15168. Epub 2020 Dec 8.
10
Venous thromboembolism in cancer patients: a population-based cohort study.癌症患者的静脉血栓栓塞症:一项基于人群的队列研究。
Blood. 2021 Apr 8;137(14):1959-1969. doi: 10.1182/blood.2020007338.